drugset / Trial / NCT00960882

Gastric Tolerability and Pharmacokinetics of DMMET-01

NCT00960882

Phase 1 Completed 12 enrolled Laboratorios Silanes S.A. de C.V.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the gastric tolerability and the pharmacokinetics of a new drug for the treatment of type 2 diabetes, DMMET-01, in healthy volunteers.

Timeline

Start
2007-06
Primary completion
2008-03
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin glycinate Unknown 1050.6 mg

Indications

No indication recorded.